Skip to main content
Journal cover image

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Publication ,  Journal Article
Galsky, MD; Balar, AV; Black, PC; Campbell, MT; Dykstra, GS; Grivas, P; Gupta, S; Hoimes, CJ; Lopez, LP; Meeks, JJ; Plimack, ER; Rosenberg, JE ...
Published in: J Immunother Cancer
July 2021

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

July 2021

Volume

9

Issue

7

Location

England

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Societies, Medical
  • Immunotherapy
  • Humans
  • Guidelines as Topic
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Galsky, M. D., Balar, A. V., Black, P. C., Campbell, M. T., Dykstra, G. S., Grivas, P., … Kamat, A. M. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer, 9(7). https://doi.org/10.1136/jitc-2021-002552
Galsky, Matthew D., Arjun V. Balar, Peter C. Black, Matthew T. Campbell, Gail S. Dykstra, Petros Grivas, Shilpa Gupta, et al. “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.J Immunother Cancer 9, no. 7 (July 2021). https://doi.org/10.1136/jitc-2021-002552.
Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer. 2021 Jul;9(7).
Galsky, Matthew D., et al. “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.J Immunother Cancer, vol. 9, no. 7, July 2021. Pubmed, doi:10.1136/jitc-2021-002552.
Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer. 2021 Jul;9(7).
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

July 2021

Volume

9

Issue

7

Location

England

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Societies, Medical
  • Immunotherapy
  • Humans
  • Guidelines as Topic
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology